FORT MILL, SC / ACCESSWIRE / February 10, 2023 / Ra Medical Systems (NYSE American:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting. Shareholders of record as of February 3, 2023 are entitled to vote at the meeting.
Among other items, shareholders are requested to vote in favor of a previously announced $8 million private financing, and to vote in favor of the conversion of RMED preferred stock into common stock, the majority of which will not be converted until mid-2024, at the earliest. The preferred stock was issued in connection with the acquisition of Catheter Precision, Inc., earlier this year.
About Ra Medical Systems
Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
CONTACTS:
At the Company
David Jenkins
973-691-2000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.38 |
| Daily Change: | -0.004 -1.03 |
| Daily Volume: | 106,176 |
| Market Cap: | US$3.060M |
November 04, 2024 August 06, 2024 January 02, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
